Literature DB >> 9435875

Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.

H H van Ojik1, R Repp, G Groenewegen, T Valerius, J G van de Winkel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9435875     DOI： 10.1007/s002620050434

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  3 in total

1.  IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

Authors:  Robin Parihar; Julie Dierksheide; Yan Hu; William E Carson
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 2.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

Review 3.  CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases.

Authors:  Olusiji A Akinrinmade; Shivan Chetty; Adebukola K Daramola; Mukit-Ul Islam; Theo Thepen; Stefan Barth
Journal:  Biomedicines       Date:  2017-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.